enGene Therapeutics News and Activities

enGene Therapeutics is a company listed under the stock ticker ENGN (CA).

Acquisition, funding and merger involving enGene Therapeutics.

• The new name of enGene is enGene Therapeutics. (posted on April 8 2026).

View the org chart displaying its 28 main executives

Most searched biographies at enGene Therapeutics

• Ron Cooper, Chief Executive Officer and Director
• Richard Glickman, Chairman of the Board
• Michael Heffernan, Director

Popular executive movements at enGene Therapeutics

• Kathleen Richton will join the company as Senior Vice President, Finance on Jul. 16, 2026  (posted on June 16 2026).
• Ryan Daws, Chief Financial Officer and Head of Business Development, will leave the company on Jul. 15, 2026  (posted on June 16 2026).

Create your alert
to follow the executive moves at enGene Therapeutics.

enGene Therapeutics has 2,425 competitors including Lonza (Switzerland), Vertex Pharmaceuticals (United States (USA)) and Eurofins (Luxembourg).

Popular M&A news in Biotechnology

• Chemomab and Scipher Medicine have announced they will merge  (posted on July 13 2026)..
• Chemomab and Scipher Medicine have announced they will merge  (posted on July 13 2026)..
• Apnimed has filed its IPO. Its stock ticker will be APMD. (posted on July 13 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Robert Gould - Board Member at Fulcrum Therapeutics

Learn more about the Biotechnology industry

Press releases by enGene Therapeutics

• enGene - In the News
• enGene Holdings Inc. News powered by B2i Technologies - SmartWireenGene Holdings Inc. News powered by B2i Technologies - SmartWire
• enGene - Communiqués de presse
• enGene - Press Releases

Social media about enGene Therapeutics

• enGene Therapeutics on Wikipedia, Google News & Yahoo Finance
• enGene Therapeutics on LinkedIn, X (Twitter) & YouTube